Диссертация (1335925), страница 27
Текст из файла (страница 27)
Marcellin, S. S. Lee [et al.] // Lancet. – 1998. – Vol. 352. – Р. 1426–1432.260. Poynard, T. Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possiblefor the first line treatment in patients with chronic hepatitis C? The algovirc project Group /T. Poynard, J. McHutchison, Z. Goodman [et al.] // Hepatology.
– 2000. – № 31. – P. 211–218.261. Poynard, T. Slow regression of liver fibrosis presumed by repeated biomarkers aftervirological cure in patients with chronic hepatitis C / T. Poynard, J. Moussali, M. Munteanu [et al.] // J.Hepatol. – 2013. – № 59. – P. 675–683.137262. Qiang Li, C. Y. ABO blood group and the risk of hepatocellular carcinoma:a case-controlstudy in patients with chronic hepatitis B / C. Y. Qiang Li, Y. Jin-Hong, Li Liu [et al.] // PLoS One. –2012.
– № 7.263. Rauch, A. Swiss Hepatitis C Cohort Study. Genetic variation in IL28B is associated withchronic hepatitis C and treatment failure: a genome-wide association study / A. Rauch, Z. Kutalik,P. Descombes [et al.] // Gastroenterology. – 2010. – V. 138, № 4. – P.1338–1345.264. Reig, M. Unexpected high rate of early tumor recurrence in patients with HCV-related HCCundergoing interferon-free therapy / M. Reig, Z. Mariño, C. Perelló [et al.] // J. Hepatol.
– 2016. –№ 65(4). – P. 719–726.265. Riva, E. Hepatitis C virus and interferon type III (interferon lambda 3/interleukin 28B andinterferon lambda 4): genetic basis of susceptibility to infection and response to antiviral treatment /E. Riva, C. Scagnolari, O. Turriziani, G.
Antonelli // Clin. Microbiol. Infect. – 2014. – Vol. 20. –№ 12. – P. 1237–1245.266. Roffi, L. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-toleratedtreatment regimen for patients with hepatitis C virus related histologically proven cirrhosis / L. Roffi,G. Colloredo, P. Pioltelli [et al.] // Antivir. Ther. – 2008. – № 13. – P. 663–673.267.
Romero, A. I. Interferon (IFN)-gamma-inducible protein-10: association with histologicalresults, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin forchronic hepatitis C virus infection / A. I. Romero, M. Lagging, J. Westin [et al.] // J. Infect. Dis. –2006. – No. 194. – P.
895–903.268. Romero, G. M. Insulin resistance im-pairs sustained response rate to peginterferon plusribavirin in chronic hep-atitis C patients / G. M. Romero, V. M. Del Mar, R. J Andrade [et al.] //Gastroenterology. – 2005. – Vol. 128. – Р. 636–641.269. Rosen, H. R. Chronic hepatitis C infection / H. R. Rosen // New England Journal ofMedicine. – 2011. – V. 364.
– № 25. – P. 2429–2438.270. Samokhvalov, E. Freguen cyofdetection of differ ent hepatitisCvirussubtypesintheMoscowregion / E. Samokhvalov, L Nikolaeva, SAl'khovskil [et al.] // Vopr. Virusol. – 2013. – № 58. – P. 36–40.271. Sarrazin, C. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1patients in the European region / C. Sarrazin, E.
Lathouwers, M. Peeters [et al.] // Antiviral. Res. –2015. – № 116. – P. 10–16.272. Sayal, S. K. Study of blood groups in HIV seropositive patients / S. K. Sayal, A. L. Das,S. K. Nema // Ind. J. Derm. Ven. Lepr. – 1996. – № 62. – P. 295–297.138273. Schmidt, W. N. Direct-acting antiviral agents and the path to interferon independence /W. N. Schmidt, D. R. Nelson, J. М. Pawlotsky [et al.] // Clin.
Gastroenterol. Hepatol. – 2014. –№ 12 (5). – P. 728–737.274. Shavakhi, A. The association of non-O blood group and severity of liver fibrosis in patientswith chronic hepatitis C infection / A. Shavakhi, M. Hajalikhani, M. Minakari [et al.] // PMID. – 2012.– № 17 (5).
– P. 466–469.275. Shintani, Y. Hepatitis C virus infection and diabetes: direct involvement of the virus in thedevelopment of insulin resistance / Y. Shintani, H. Fujie, H. Miyoshi [et al.] // Gastroenterology. –2004. – Vol. 126. – P. 840–848.276. Shiratori, Y. Histologic improvement of fibrosis in patients with hepatitis C who havesustained response to interferon therapy / Y.
Shiratori, F. Imazeki, M. Moriyama [et al.] // Ann. Intern.Med. – 2000. – № 132. – P. 517–524.277. Simmons, B. Longterm treatment outcomes of patients infected with hepatitis C virus:systematic review and meta-analysis of the survival benefit of achieving a sustained virologicalresponse / B. Simmons, J. Saleem, K. Heath [et al.] // Clin. Infect. Dis. – 2015. – № 61. – P. 730–740.278. Smith, K. R.
Identification of improved IL28B SNPs and haplotypes for prediction of drugresponse in a treatment of hepatitis C using massively parallel sequencing in a cross-section Europeancohort / K. R. Smith, V. Suppiah, K. O’Connor [et al.] // Genome. Med. – 2011. – Vol. 3, № 8. – P.
57.279. Stattermayer, A. Impact of IL28B genotype on the early and sustained virologic response intreatment-naive patients with chronic hepatitis С / A. Stattermayer, R. Stauber, H. Hofer [et al.] // Clin.Gastroenterol. Hepatol. – 2011. – № 9 (4). – P. 344–350.280. Polymorphisms of interferon-λ4 and IL28B – effects on treatment response tointerferon/ribavirin in patient with chronic hepatitis C // A.
F. Stattermayer, R. Strassl, A. Maieron [etal.] // Aliment. Pharmacol. Ther. – 2014. – Vol. 39. – P. 104–111.281. Stedman, C. Sofosbuvir, a NS5Bpolymerase inhibitor in the treatment ofhepatitis C: areview of its clinical potential / C. Stedman // Ther. Adv. Gastroenterol. – 2014. – № 7 (3). – P. 131–40.282. Sterling, R. K. Steatohepatitis: Risk factors and impact on disease severity in humanimmunodeficiency virus/hepatitis C virus coinfection / R. K.
Sterling, M. J. Contos, P. G. Smith //Hepatology. – 2008. – Vol. 47, № 4. – P. 1118–1127.283. Strauss, R. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patientsin Sweden – a low endemic country/ R. Strauss, A. Törner, A. S.
Duberg, R. Hultcrantz, K. Ekdahl // J.of Viral. Hepatitis. – 2008. – V. 15, № 7. – P. 531–537.284. Sulkowski, M. Treatment of hepatitis С in HIV-infected persons: awork in progress /M. Sulkowski // J. Hepatol. – 2008. – № 48 (1). – P. 5–7.139285. Suppiah, V. IL28B is associated with response to chronic hepatitisC interferonalpha andribavirin therapy / V. Suppiah, M. Moldovan, G. Ahlenstiel [et al.] // Nat.
Genet. – 2009. – V. 41,№ 10. – P. 1100–1104.286. Svarovskaia, E. S. Infrequent development of resistance in genotype 1–6 hepatitis C virusinfected subjects treated with sofosbuvir in phase 2 and 3 clinical trials / E. S. Svarovskaia, H. DvorySobol, N. Parkin [et al.] // Clin. Infect. Dis. – 2014.
– № 59. – P. 1666–1674.287. Swain, M. Sustained virologic response result-ing from treatment with peginterferon alfa-2aalone or in combination with ribavirin is durable and constitutes a cure: an ongoing 5-year follow-up /M. Swain, M.
Lai, M. L. Shiffman [et al.] // Gastroenterology. – 2007. – Vol. 132. – Р. 741A.288. Tachi, Y. Progressive fibrosis significantly correlates with hepatocellular carcinomainpatients with a sustained virological response / Y. Tachi, T. Hirai, A. Miyata [et al.] // Hepatol. Res.2015. – № 45. – P. 238–246.289. Tamaki, N. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCVRelated Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatmentwith New Regimens / N. Tamaki, M.
Kurosaki, M. Higuchi [et al.] // PLoS ONE. – 2015. – № 10 (9).– P. e0137351 [doi:10.1371/journal.pone.0137351].290. Tanaka, Y. Genome-wide association of IL28Bwith response to pegylated interferon-alphaand ribavirin therapy for chronic hepatitis C / Y. Tanaka, N. Nishida, M. Sugiyama [et al.] // Nat.Genet. – 2009. – № 41. – P. 1105–1109.291.
Thomas, D. L. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus /D. L Thomas., C. L. Thio, M. P. Martin [et al.] // Nature. – 2009. – V. 461. – P. 798–801.292. Thomas, E. HCV infection induces a unique hepatic innate immune response associatedwith robust production of type III interferons / E. Thomas, V. D. Gonzalez, Q. Li [et al.] //Gastroenterol. – 2012. – № 142.
– P. 978–988.293. Thompson, A. Interleukin-28B polymorphismimproves viral kinetics and is the strongestpretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus / A. Thompson,A. J. Muir, M. S. Sulkowski [et al.] // Gastroenterology. – 2010. – № 139. – P. 120–129.294.
Thomson, B. J. Response rates to combination therapy for chronic HCV infection in aclinical setting and derivation of probability tables for individual patient management / B. J. Thomson,G. Kwong, S. Ratib [et al.] // J. Viral. Hepat. – 2008. – Vol. 15. – Р. 271–278.295. Vierling, J. M. Sustained Virologic Response in Prior PR Treatment FailuresAfterRetreatment With Boceprevir and PR: Final Results of the PROVIDE Study / J.
M. Vierling //Digestive Disease Week. – 2013, Orlando. – 869 p.140296. Vito Di, M. IL28B polymorphisms influence stage of fibrosis and spontaneous orinterferon-induced viral clearance in thalassemia patients with hepatitis C virus infection / Marco VitoDi, F. Bronte, V. Calvaruso [et al.] // Haematologia. – 2012. – № 97 (5). – P. 679–686.297. Vogel, F. ABO blood groups and diseases / F. Vogel // Amer. J. Hum. Genet.
– 1970. –Vol. 22. –P. 464.298. Wells, G. The Newcastle-Ottawa Scale (NOS) for assessing thequality of nonrandomizedstudies inmeta-analyses / G. Wells, B. Shea, D. O’Connell [et al.]. – 2009.299. WHO, Hepatitis C [Electronic resonrce] // Fact. sheet. – 2014. – № 164. – URL:http://www.who.int/mediacentre/factsheets/fs164/en/.300. WHO.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
